These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23853602)

  • 1. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
    Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
    PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
    Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
    [No Abstract]   [Full Text] [Related]  

  • 3. Highly Effective Soluble and Bacteriophage T4 Nanoparticle Plague Vaccines Against Yersinia pestis.
    Tao P; Mahalingam M; Rao VB
    Methods Mol Biol; 2016; 1403():499-518. PubMed ID: 27076150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of
    Tong Z; Zhang X; Guo X; Wu G; Cao S; Zhang Y; Meng X; Wang T; Wang Y; Song Y; Yang R; Du Z
    mSphere; 2024 Sep; 9(9):e0033024. PubMed ID: 39158304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
    Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
    Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
    Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.
    Goodin JL; Nellis DF; Powell BS; Vyas VV; Enama JT; Wang LC; Clark PK; Giardina SL; Adamovicz JJ; Michiel DF
    Protein Expr Purif; 2007 May; 53(1):63-79. PubMed ID: 17293124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
    Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
    Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Protection Against
    Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
    Front Immunol; 2022; 13():793382. PubMed ID: 35154110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
    Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
    Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
    PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of an immunogenic F1-V fusion protein in lettuce as a plant-based vaccine against plague.
    Rosales-Mendoza S; Soria-Guerra RE; Moreno-Fierros L; Alpuche-Solís AG; Martínez-González L; Korban SS
    Planta; 2010 Jul; 232(2):409-16. PubMed ID: 20461403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
    Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
    Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
    Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
    Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague.
    Goodin JL; Powell BS; Enama JT; Raab RW; McKown RL; Coffman GL; Andrews GP
    Protein Expr Purif; 2011 Mar; 76(1):136-44. PubMed ID: 21055471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.